Synchrony Medical Closes $5 Million Funding Round for LibAirty™ Device Expansion

Synchrony Medical Secures $5 Million for Growth

In a significant move to revolutionize respiratory care, Synchrony Medical, a leading technology company specializing in respiratory treatments, has successfully secured $5 million in funding. This financing comes from various sources, notably led by Edge Medical Ventures, with contributions from the New Jersey Economic Development Authority (NJEDA) and other angel investors. This funding aims to bolster the commercial expansion of the FDA-cleared LibAirty™ Airway Clearance System in the United States.

The LibAirty™, designed to assist patients with chronic lung conditions, offers a home-based airway clearance therapy that has been shown to outperform traditional methods by effectively clearing up to twice as much sputum. This innovative system not only enhances the user experience but also addresses a critical need for effective management of chronic respiratory diseases.

Anat Shani, the CEO of Synchrony Medical, expressed her enthusiasm regarding the funding, stating, "This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health." This statement underscores the company's commitment to improving patient autonomy in managing their conditions effectively and comfortably.

Since its commercial launch in late 2025, the LibAirty™ system has garnered positive attention from both healthcare providers and patients, marking its initial impact in the field of respiratory care. The technology has been positively received as a reliable solution to managing respiratory ailments, facilitating day-to-day health maintenance for those affected.

The recent funding will not only enhance Synchrony’s commercial reach but also support ongoing clinical research and product innovations. Notably, the investment included $1 million from the NJEDA through the New Jersey Innovation Evergreen Fund (NJIEF), further solidifying the company’s roots in New Jersey.

In line with the funding announcement, Synchrony also revealed two new appointments to its Board of Directors: Kevin Kotler, General Partner of Broadfin Holdings, and Elad Duschak, Strategic Advisor to CBG for Healthcare. Their expertise is expected to provide strategic oversight as Synchrony embarks on this next phase of growth, particularly in expanding its clinical evidence and innovation capabilities.

Kevin Kotler commented on the potential of the LibAirty™ system, stating, "The LibAirty™ System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth." This insight reflects confidence in the product's ability to significantly enhance patient care and establish a new standard in respiratory management.

Synchrony is dedicated to expanding its U.S. presence and operations from its headquarters in Jersey City, with plans to scale while continuing to innovate in the airway clearance space. As it develops its capabilities further, Synchrony aims to leverage the financial backing to improve accessibility of the LibAirty™ system for patients across the country.

Shai Policker, Chairman of Synchrony, elaborated on the strategic vision for Synchrony Medical, noting, "Synchrony exemplifies the type of innovation we seek to support, addressing an unmet clinical need through strong clinical foundations and a clear path to transforming patient care." This reflects the broader goals of health innovation, striving for a paradigm shift in how patients engage with their respiratory treatments.

As the company forges ahead with its initiatives, Synchrony Medical remains committed to empowering patients with effective and accessible healthcare solutions, ensuring a better quality of life for those living with chronic respiratory conditions.